As more and more baby boomers have signed on for testosterone testing--and, in turn, therapy--worries about the safety of testosterone-boosting drugs have grown. Now, a new study in the Journal of the American Medical Association puts some numbers to that concern.
A year after Curis agreed to pay Genentech $9.5 million upfront to license the early-stage cancer therapy recoded as CUDC-427 and borrowed $30 million to launch its own study, the FDA has clamped a partial clinical hold on the program following the death of one patient taking the drug.
Australian Prana Biotechnology has published new data showing its metal-transporting compound PBT2 reversed memory and learning loss associated with the aging process in elderly mice.
The FDA has asked drugmakers to recall several products with dosing systems or potency variations that could lead to dangerous overdoses.
With a plummeting share price and grim prospects for its lead drug, Ariad Pharmaceuticals is adopting a shareholder rights plan to deter would-be corporate raiders, a move to protect what little value it has left.
Shares of badly battered Ariad Pharmaceuticals took a fresh dive this morning after the biotech reported that it is jerking its leukemia drug Iclusig from the market, two weeks after the drug developer opted to shutter its Phase III confirmatory study after seeing evidence of an elevated risk of blood clots among patients.
Once expected to crest at $2.52 billion a year, most analysts now don't see AstraZeneca's blood-thinner Brilinta hitting the $1 billion blockbuster mark, with a poor impact in the U.S. market dragging down projections.
When the FDA puts drugs on the fast track for approval, they do make it to market sooner. But they're tested for a shorter period of time than are drugs reviewed under the agency's standard process, according to a new study in the Journal of the American Medical Association. And that has researchers worried.
The FDA's move to put tighter controls on combo pain drugs like Vicodin that contain hydrocodone with over-the-counter painkillers like aspirin have it again balancing its role as a regulator concerned about the safety and effectiveness of drugs with growing concerns about overdose deaths and addition.
A new study finds that the drug lingers in the bodies of patients long after they've stopped using it, sometimes even for years.